Radionuclide Leptomeningeal Metastasis Therapy Trials

Franklin C.L. Wong

doi:10.1007/978-3-031-14291-8_8

Radionuclide Leptomeningeal Metastasis Therapy Trials

Franklin C.L. Wong

Nuclear Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The rationales for published intrathecal radionuclide for leptomeningeal metastasis (LM) therapy trials with radiopharmaceuticals are reviewed. The radioactivity dosing schemes, efficacy, and toxicity profiles are compared. The potential use of radiation dosimetry to guide intrathecal radionuclide therapy is also reviewed. The trends, practical, and logistic aspects of intrathecal radionuclide therapy of LM are outlined.

Original language	English (US)
Title of host publication	Radiopharmaceuticals in the Management of Leptomeningeal Metastasis
Publisher	Springer International Publishing
Pages	149-159
Number of pages	11
ISBN (Electronic)	9783031142918
ISBN (Print)	9783031142901
DOIs	https://doi.org/10.1007/978-3-031-14291-8_8
State	Published - Jan 1 2022

Keywords

Au-198
Colloid
I-125-IUDR
I-131 Monoclonal antibody
Omburtamab
P-32

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-14291-8_8

Cite this

@inbook{6faba15bedbf42ee86212f3c8ba1b06a,

title = "Radionuclide Leptomeningeal Metastasis Therapy Trials",

abstract = "The rationales for published intrathecal radionuclide for leptomeningeal metastasis (LM) therapy trials with radiopharmaceuticals are reviewed. The radioactivity dosing schemes, efficacy, and toxicity profiles are compared. The potential use of radiation dosimetry to guide intrathecal radionuclide therapy is also reviewed. The trends, practical, and logistic aspects of intrathecal radionuclide therapy of LM are outlined.",

keywords = "Au-198, Colloid, I-125-IUDR, I-131 Monoclonal antibody, Omburtamab, P-32",

author = "Wong, {Franklin C.L.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-14291-8_8",

language = "English (US)",

isbn = "9783031142901",

pages = "149--159",

booktitle = "Radiopharmaceuticals in the Management of Leptomeningeal Metastasis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Radionuclide Leptomeningeal Metastasis Therapy Trials

AU - Wong, Franklin C.L.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The rationales for published intrathecal radionuclide for leptomeningeal metastasis (LM) therapy trials with radiopharmaceuticals are reviewed. The radioactivity dosing schemes, efficacy, and toxicity profiles are compared. The potential use of radiation dosimetry to guide intrathecal radionuclide therapy is also reviewed. The trends, practical, and logistic aspects of intrathecal radionuclide therapy of LM are outlined.

AB - The rationales for published intrathecal radionuclide for leptomeningeal metastasis (LM) therapy trials with radiopharmaceuticals are reviewed. The radioactivity dosing schemes, efficacy, and toxicity profiles are compared. The potential use of radiation dosimetry to guide intrathecal radionuclide therapy is also reviewed. The trends, practical, and logistic aspects of intrathecal radionuclide therapy of LM are outlined.

KW - Au-198

KW - Colloid

KW - I-125-IUDR

KW - I-131 Monoclonal antibody

KW - Omburtamab

KW - P-32

UR - http://www.scopus.com/inward/record.url?scp=85160158942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160158942&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-14291-8_8

DO - 10.1007/978-3-031-14291-8_8

M3 - Chapter

AN - SCOPUS:85160158942

SN - 9783031142901

SP - 149

EP - 159

BT - Radiopharmaceuticals in the Management of Leptomeningeal Metastasis

PB - Springer International Publishing

ER -

Radionuclide Leptomeningeal Metastasis Therapy Trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this